183 related articles for article (PubMed ID: 31583102)
1. Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions.
Hammoudeh S; Gadelhak W; AbdulWahab A; Al-Langawi M; Janahi IA
Multidiscip Respir Med; 2019; 14():29. PubMed ID: 31583102
[TBL] [Abstract][Full Text] [Related]
2. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of the cystic fibrosis phenotype in a large kindred family in Qatar with cystic fibrosis mutation (I1234V).
Abdul Wahab A; Al Thani G; Dawod ST; Kambouris M; Al Hamed M
J Trop Pediatr; 2001 Apr; 47(2):110-2. PubMed ID: 11336127
[TBL] [Abstract][Full Text] [Related]
4. Advances in Cystic Fibrosis Research in Qatar: A Commentary.
Hammoudeh S; Janahi IA
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983631
[TBL] [Abstract][Full Text] [Related]
5. Faecal elastase-1 concentration in cystic fibrosis patients with CFTR I1234V mutation.
Abdel Rahman H; Abdul Wahab A; Abdel Rahman MO; Mostafa OA
Acta Paediatr; 2006 Sep; 95(9):1066-9. PubMed ID: 16938751
[TBL] [Abstract][Full Text] [Related]
6. Cystic fibrosis mutation I1234V in a Qatari lady.
Wahab AA
J Trop Pediatr; 2003 Feb; 49(1):54-5. PubMed ID: 12630722
[TBL] [Abstract][Full Text] [Related]
7. First report of the cystic fibrosis transmembrane conductance regulator mutation c.1521_1523delCTT (p. Phe508del) in two Qatari patients with cystic fibrosis.
AbdulWahab A; AlNaimi A; Habra B; Janahi I
Qatar Med J; 2021; 2021(1):24. PubMed ID: 34377682
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review.
Al-Sadeq D; Abunada T; Dalloul R; Fahad S; Taleb S; Aljassim K; Al Hamed FA; Zayed H
Respirology; 2019 Feb; 24(2):127-136. PubMed ID: 30419605
[TBL] [Abstract][Full Text] [Related]
9. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population.
Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M
Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817
[TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.
Ooi CY; Durie PR
J Cyst Fibros; 2012 Sep; 11(5):355-62. PubMed ID: 22658665
[TBL] [Abstract][Full Text] [Related]
11. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR
Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
13. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
[TBL] [Abstract][Full Text] [Related]
14. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
[TBL] [Abstract][Full Text] [Related]
15. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
[TBL] [Abstract][Full Text] [Related]
16. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations.
Kerem E; Rave-Harel N; Augarten A; Madgar I; Nissim-Rafinia M; Yahav Y; Goshen R; Bentur L; Rivlin J; Aviram M; Genem A; Chiba-Falek O; Kraemer MR; Simon A; Branski D; Kerem B
Am J Respir Crit Care Med; 1997 Jun; 155(6):1914-20. PubMed ID: 9196095
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
19. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
20. On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.
Yu YC; Sohma Y; Hwang TC
J Physiol; 2016 Jun; 594(12):3227-44. PubMed ID: 26846474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
